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Differences in manufacturing processes can affect the
properties of biological products. This is especially true for
products based on botulinum toxin. The manufacturing
process for Xeomin/Bocouture (NT 201, incobo-
tulinumtoxinA, INCO) employs chromatographic methods
and produces a pure neurotoxin without any other bacterial
contaminants such as the so-called complexing proteins or
clostridial DNA. In contrast, Botox/Vistabel (onabo-
tulinumtoxin, ONA) is produced with precipitation tech-
niques resulting in a complex composed of several
proteins.
As Dr. Jost [1] points out, a comparison of the potencies
of the preparations based merely on different bioassays is
not sufficient. The active ingredient in all botulinum toxin
products is of course the neurotoxin, but in the absence of
international standards for the activity of BoNTA products,
each manufacturer employs its own proprietary biological
assay for testing potency units, which in principle differ
from company to company and might provide different
results. Neither a mouse lethal dose (LD50 assay) nor
molecular effect in a cellular assay correctly reflects the
therapeutic situation (e.g., on a dystonic muscle). As stated
in the article, these assays also depend on the testing
conditions; for example, the composition of the diluent,
which is critical for the low concentration of the neuro-
toxin. The SNAP 25 cleavage assay only measures one part
of the activity of the neurotoxin.
To determine any differences in potency, the products
have to be compared in clinical head-to-head studies.
Perhaps the most scientifically valid studies to date are two
which were conducted in patients with blepharospasm and
cervical dystonia [2, 3]. These were large, rigorous, dou-
ble-blind, randomized, non-inferiority trials, in which
participants had a stable therapeutic response on ONA
before study start with maintenance of the same dose
regimen during the trial. Both showed that INCO, when
administered at the same doses as prior successful ONA
treatment, was noninferior in clinical efficacy to ONA. In a
subsequent review article summarizing results from studies
in focal dystonia, Dr. Jost states: ‘‘This approach…indi-
cated that equal units of NT 201 have a comparable safety
and efficacy profile to BOT and both phase III studies
supported the dose ratio of 1:1’’ [4].
In aesthetic medicine, the most rigorous study to date is
that of Sattler et al. [5]. This randomized 381 patients in a
3:1 ratio to receive 24 U of INCO or ONA for the treatment
of glabellar frown lines. There was no difference in initial
activity and the authors of the paper concluded that both
treatments were equally effective over at least 12 weeks. It
is therefore surprising that in his commentary Dr. Jost
makes reference to a study by Moers-Carpi et al. [6], in
which different doses of ONA and INCO were compared in
the treatment of glabellar lines. The study purported to
show that 20 U of ONA was as effective as 30 U of INCO
in reducing the severity of glabellar lines 28 days post-
injection, but was flawed in that it did not include an arm
comparing 30 U ONA with 20 U INCO. When Prager and
Rappl [7] published a similar study with the missing arm
(20 U INCO and 30 U ONA), the clinical effect was the
same despite the 50 % difference in dose. Taken together,
both studies result in a conversion ratio of 1:1 for ONA
versus INCO, again confirming the conclusion from the
registration studies.
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The author agrees that for aesthetic indications the in-
cidence of neutralizing antibodies against botulinum neu-
rotoxin is low, partly because the relatively low doses used
minimize the potential for their formation. However, the
composition of the products is important. The immune
system requires a signal to become activated against an
antigen. Some of the complexing proteins present in ONA
and ABO are hemagglutinins, which bind to immune cells
leading to their activation. Dr. Jost is correct in stating that
all evidence demonstrating the immune-stimulating effect
of complexing proteins is currently based on preclinical
studies. Furthermore, all statements concerning clinical
differences are retrospective, and no head-to-head clinical
studies have analyzed differences in the immunological
potential of the different botulinum toxin products. How-
ever, after almost 10 years on the market and around 1
million treated patients, no antibody production has been
observed in treatment-naı¨ve patients receiving INCO. It
therefore seems justified to draw the conclusion that re-
moval of the superfluous proteins reduces the risk of neu-
tralizing antibody formation and the potential for
subsequent treatment failure. Considering that patients
treated with ONA or ABO require a shortened injection
interval to prevent the reoccurrence of symptoms before
the usually applied 12-week injection intervals, the use of
INCO has been shown to be tolerable and efficacious [8].
What does all this mean for the practicing physician? If
a product with less biological activity were administered
for therapeutic indications at unit doses based on a more
potent product, patients may not experience adequate re-
duction in symptoms. For aesthetic indications, the results
may not meet patient expectations, which could lead to
dissatisfaction. With INCO this is clearly not the case and
switching from an established effective dose of ONA to the
same number of labeled units of INCO can be expected to
provide a similar clinical result.
Given the differences in manufacturing processes be-
tween ONA and INCO, and the presence (ONA) or absence
of complexing proteins (INCO), the products are definitely
not identical. Are they similar in terms of treatment out-
come for the same indications at the same unit dose? Yes.
The usage of either of the different BoNT products
should always follow the instructions of the respective
approved product label.
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